Safety and Efficacy of PRO 542 in the Treatment of HIV-Infected Patients
NCT00055185
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
24
Enrollment
INDUSTRY
Sponsor class
Conditions
HIV Infections
Acquired Immune Deficiency Syndrome
Interventions
DRUG:
CD4-IgG2 (PRO 542)
Sponsor
Progenics Pharmaceuticals, Inc.